3-HO-PCE

Not to be confused with 3-HO-PCP.

Summary sheet: 3-HO-PCE

3-HO-PCE
Chemical Nomenclature
Common names	3-HO-PCE, Hydroxyeticyclidine
Substitutive name	3-Hydroxyeticyclidine
Systematic name	3-[1-(Ethylamino)cyclohexyl]phenol
Class Membership
Psychoactive class	Dissociative
Chemical class	Arylcyclohexylamine
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Oral Dosage Threshold 5 mg Light 5 - 10 mg Common 10 - 15 mg Strong 15 - 25 mg Heavy 25 mg + Redosing may result in dangerous cumulative effects. Duration Total 4 - 6 hours DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions
Stimulants
Depressants

3-Hydroxyeticyclidine (commonly known as 3-HO-PCE) is a novel synthetic dissociative substance of the arylcyclohexylamine chemical class. It produces potent, dose-sensitive dissociative, hallucinogenic and euphoric effects when administered. Unlike its close structural analog 3-HO-PCP, this compound has no precedent in the scientific literature before being offered on the research chemicals market in the 2010s.

Early discussions of this compound have revolved around whether it possesses an appreciable affinity for the μ-opioid receptor given its structural relationship to 3-HO-PCP, which has been shown to display affinity for the μ-opioid receptor in animal models. Whether it produces any of its theorized opioid effects in humans is the subject of ongoing discussion. If it does, 3-HO-PCE may pose unique risks relative to other dissociatives, particularly when it is redosed.

Following other substances of its class, particularly methoxetamine (MXE), phencyclidine (PCP), and 3-MeO-PCE, it is speculated to to be able to induce a state known as "dissociative anesthesia". Early reports suggest that this state is difficult to reach relative to other dissociatives, and its general effects profile has been characterized as "lying halfway between 3-MeO-PCP and 3-MeO-PCE."

There is a lack of data of the pharmacological properties, metabolism and toxicity of 3-HO-PCE. To date, there have been no analytical studies conducted on samples of 3-HO-PCE distributed through the grey market via independent laboratories. Due to an unknown toxicity profile and likely similar habit-forming properties shared by other hydroxylanated arylcyclohexylamines, it is strongly recommended that one use proper harm reduction practices if choosing to use this substance.

History and culture

This History and culture section is a stub. As a result, it may contain incomplete or wrong information. You can help by expanding it.

On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, which includes 3-HO-PCE.

Chemistry

3-HO-PCE, or 3-hydroxyeticyclidine, is a synthetic dissociative of the arylcyclohexylamine class. The structure of 3-HO-PCE is comprised of cyclohexane, a six-member saturated ring, bonded to two additional groups at R₁. One of these an ethyl chain bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R₃ with a hydroxy group.

3-HO-PCE is an analog of PCE and structurally homologous to 3-MeO-PCE.

Pharmacology

Further information: NMDA receptor antagonist

While no formal studies have been conducted, 3-HO-PCE likely acts principally as an NMDA receptor antagonist.

The NMDA (N-Methyl-D-Aspartate) receptor, a specific subtype of glutamate receptor, modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.

Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia.

There is ongoing speculation as to whether this compound possesses μ-opioid receptor activity due to its structural relationship to 3-HO-PCP, which has been found to have appreciable affinity as a μ-opioid receptor agonist in animal models.

Subjective effects

This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

• The physical effects of this substance have been reported to be relatively unpronounced or difficult to detect.
  • Stimulation & Sedation
  • Tactile enhancement & Tactile suppression - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and anesthesia.
  • Pain relief - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only at higher doses.
  • Motor control loss
  • Changes in felt gravity
  • Spatial disorientation - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.
  • Increased blood pressure
  • Increased heart rate
  • Increased perspiration
  • Respiratory depression
  • Physical autonomy
  • Olfactory hallucinations
  • Optical sliding
  • Appetite suppression
  • Dehydration
  • Dizziness
  • Difficulty urinating
  • Seizure - This extent to which this effect can be produced is unknown but can likely happen in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, undernourished, overheated, or fatigued.

Disconnective effects

• The disconnective effects of this compound appear to be less prominent compared to dissociatives like ketamine or MXE. They seem to not occur at common doses and may only occur at levels that may be accompanied by potentially dangerous side effects.
  • Tactile disconnection
  • Visual disconnection
  • Consciousness disconnection

Cognitive effects

• • Anxiety suppression
  • Compulsive redosing - This effect is more prominent based on the route of administration used. For example, it is especially present when smoked or vaporized, due to the relative abruptness of the substance entering and leaving the bloodstream.
  • Conceptual thinking
  • Mania - This effect is reportedly more common on 3-HO-PCE than most other dissociatives.
  • Depersonalization
  • Derealization
  • Disinhibition
  • Psychosis
  • Delusion
  • Cognitive euphoria
  • Memory suppression
    • Ego death
    • Amnesia
  • Immersion enhancement
  • Increased music appreciation
  • Time distortion
  • Thought deceleration
  • Thought disorganization

Auditory effects

• • Suppression
  • Distortions
  • Hallucinations

Visual effects

• • Visual acuity suppression - While lower doses of this compound may produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increase.
  • Frame rate suppression
  • Pattern recognition suppression

  Distortions

  • Perspective distortions
  • Scenery slicing

  Hallucinatory states

  • Internal hallucination (settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots)

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

• Erowid Experience Vaults: 3-HO-PCE

Toxicity and harm potential

This toxicity and harm potential section is a stub. As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational 3-HO-PCE use has not been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-HO-PCE has a very short history of human usage.

Tolerance and addiction potential

Early reports have characterized the chronic use of 3-HO-PCE as moderately addictive with a moderate potential for adverse side effects such as psychosis. In comparison to other dissociatives, 3-HO-PCE has been reported to be more potentially habit-forming than MXE, diphenidine, ephenidine, DCK, and ketamine. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 3-HO-PCE is expected to develop with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 4 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-HO-PCE presents cross-tolerance with all dissociatives, meaning that after the consumption of 3-HO-PCE, all dissociatives will have a reduced effect.

It is strongly recommended that one exercise extreme caution and harm reduction practices when using this substance.

• Users should avoid taking the drug multiple days in a row or becoming dependent/addicted to it as this seems to be the main common factor in the observed incidences of severe adverse effects.
• The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
• Users should start with extremely low doses and work their way up as slowly as possible. Volumetric liquid dosing should preferably be used due to the substance's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.
• Compulsive redosing before one has fully sobered up is not recommended and can result in too high of a dose, which can potentially produce serious adverse physical side effects.

Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially stimulants, psychedelics, or other dissociatives. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-HO-PCE is likely to exhibit similar bladder and urinary tract problems to those produced by ketamine, albeit to a lesser extent. This has been speculated to be due to the fact 3-HO-PCE is far more potent than ketamine so significantly less of material needs to be consumed. Symptoms of dissociative-induced cystitis can become extremely serious and can be described as:

• Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
• Urinary urgency - This can be described as a sudden, compelling need to urinate.
• Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
• Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
• Hematuria - This is visible blood in the urine.
• Incontinence - This is the leakage of urine.

Dangerous interactions

• Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
• Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.

Legal status

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

• Germany: 3-HO-PCE is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
• Sweden: 3-HO-PCE is not a controlled substance for research purposes. It is illegal to consume.
• Switzerland: 3-HO-PCE is a controlled substance specifically named under Verzeichnis E.
• Turkey: 3-HO-PCE is a classed as drug and is illegal to possess, produce, supply, or import.
• United Kingdom: 3-HO-PCE is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with a hydroxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.

See also

• Responsible use
  • Volumetric dosing
• Research chemical
• Dissociatives
• Arylcyclohexylamines
• 3-MeO-PCP
• 3-HO-PCP
• PCP

External links

• 3-HO-PCE (Isomer Design)

Discussion

• The Big & Dandy 3-HO-PCE Thread (Bluelight)
• Interview with a Ketamine Chemist (VICE)

Literature

• Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620